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Summary
Obesity is a well-known risk factor of abnormal carbohydrate and lipid metabolism, arterial hypertension, and 
cardiovascular diseases. This risk increases with abnormal fat distribution with excessive fat accumulation in the 
abdominal cavity, liver, pancreas, heart, kidneys, blood vessels, and muscles. In this review we present pathogenesis, 
diagnostic challenges and metabolic consequences of visceral and sarcopoenic obesity — the new phenotypes of fat 
distribution in human evolution.
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Background
The incidence of obesity systematically increases, 
which has a significant impact on global mortality rate, 
financial burden due to incapacity for work, and in-
creased health care costs. It has been estimated that 
obesity, expressed as the body mass index (BMI) above 
25 kg/m2, affects approximately 37% of men and 38% 
women of the world population. This, in turn, is relat-
ed to increasing rates of the diseases that are associated 
with excess body fat, such as abnormal carbohydrate or 
lipid metabolism, hypertension and atherosclerosis [1]. 
However, it is widely accepted that the risk of these met-
abolic disorders is associated rather with fat distribution 
than excess body fat per se, particularly with new, in the 
context of human evolution, phenotypes of abnormal 
fat distribution: visceral obesity and sarcopoenic obesity.
Visceral obesity
Abdominal obesity, composed of excess visceral fat 
(VF) and excess subcutaneous fat within the abdomi-
nal area, is one of the main diagnostic criteria for 
the metabolic syndrome. Visceral obesity is defined 
as excessive fat accumulation in the omentum, mes-
entery, intestine and intra-abdominal organs. High 
prevalences of visceral obesity are primarily attribut-
ed to unfavourable contemporary lifestyle which may 
be overlapped by genetic and environmental factors. 
VF is composed of adipocytes which show several 
morphological and functional differences in compar-
ison with those in the subcutaneous fat.
First, adipocytes in VF are usually hypertrophic, 
unstable and break easily in response to mechanical 
or humoral stimulation releasing triglycerides, fatty 
acids and diacylglycerols into the blood stream [2]. 
Second, a low expression of the insulin and adrenergic 
a2 receptors and high expression of the adrenergic b3 
receptors promotes lipolysis, which contributes to the 
development of insulin resistance [3]. Third, VF is 
easily infiltrated by macrophages, resulting in the in-
creased production of interleukins (IL), predominant-
ly IL-6 and IL-8, tumour necrosis factor a (TNFa), 
macrophage colony stimulating factor (MCSF) 
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Table I. Risk factors for visceral obesity
Age
Gender (males)
Low testosterone and dehydroepiandrosterone levels (males)
Hyperandrogenism (females)
Polycystic ovary syndrome
Increased activation of endocannabinoid system 
Grow hormone deficiency
Excess of egzo- and endogenic glucocorticoids (stress, Cushing 
disease)
Coexisting autoimmune diseases
Dietary factors: excessive intake of fructose, saturated fatty acids 
and calories leading to increase in free fatty acids concentrations  
in plasma
Low physical activity
Impaired quantity and quality of sleep
and other proinflammatory cytokines, which overall 
induce a low grade chronic immune inflammation. 
In addition, in the insulin receptor f VF adipocytes 
the serine phosphorylation and tyrosine dephosphor-
ylation processes are impaired, which may further en-
hance insulin resistance [4–6] — a key process in the 
pathogenesis of type 2 diabetes (T2DM). Finally, the 
glucocorticoid receptors are overexpressed in VF [7]. 
Glucocorticoids are known to accelerate the differ-
entiation and inhibit proliferation of adipocytes, 
leading to their hypertrophy [7, 8]. Based on this 
observation, several concepts linking hyperprolifera-
tion of adipocytes in the VF and increased glucocor-
ticoids concentration in response to stress have been 
developed [9, 10].
Factors initiating visceral fat accumulation
It has been suggested that chronic psychological 
stress or impaired coping with stress may induce 
a moderate hypercortisolism and activation of the 
sympathetic nervous system but with no essential 
influence on the hypothalamic-pituitary-adrenal axis. 
Studies showed that in VF there is a high expres-
sion of the 11b-hydroxysteroid dehydrogenase type 1 
(11bHSD), which is a microsomal enzyme catalysing 
conversion of cortisone to cortisol. The increased 
activity of 11bHSD stimulates VF proliferation, es-
pecially on high-fat diet [11, 12], which contributes 
to increases in fat cells size and lipolysis [13]; these 
processes do not seem to depend on the level of obe-
sity and body composition [14].
Aside from direct glucocorticoid effects, many en-
vironmental factors associated mainly with contem-
porary life style, dietary habits, and comorbidities 
have been identified and related to visceral obesity 
(Table I) [13, 15, 17, 18]. Eating food containing 
processed fructose and saturated fat has been recog-
nized as the strongest dietary factor that increases the 
VF formation, while the Mediterranean diet shows 
the opposite effect [18]. In a broader sense, all these 
factors can be considered as potential stressors and 
therefore they are likely to induce a chronic inflam-
matory process in a similar way that is observed in 
conditions with excess of endogenous glucocorti-
coids.
Assessment of visceral fat
Until recently, computed tomography (CT) and 
magnetic resonance imaging (MRI) have been the 
only available techniques to assess VF. However, 
these techniques are costly, time-consuming or asso-
ciated with a risk of radiation. Therefore, other imag-
ing techniques have been developed to quantify VF. 
Of them, dual-energy X-ray absorptiometry (DXA) 
seems to provide the most promising results. In the 
standard DXA whole body scan, newly developed 
application CoreScan® automatically calculates VF 
by subtracting the abdominal subcutaneous fat from 
total abdominal fat (Figure 1). Time of this examina-
tion is relatively short and patient’s irradiation low 
[19, 20]. DXA-derived VF is well correlated with VF 
calculated CT (R2 = 0.957) [21].
The main limitation of these imaging techniques 
in determining the risk of cardiometabolic diseases 
is the lack of universally accepted cut values for VF 
mass and volume that makes it unable to define the 
visceral obesity based on the results of CT, MRI, and 
DXA measurements. In observational studies, the VF 
area in the CT scan above 110−130 cm2 was found 
as the predictor of cardiovascular disease, dyslipidae-
mia and insulin resistance [22, 23] but other studies 
proposed different cut-offs [24]. On the other hand, 
using the CoreScan application we have recently 
demonstrated that normal values of VF volume and 
mass in young healthy women were 250.3 ± 194 cm3 
and 235.9 ± 183 g, respectively [25]; however, these 
should be confirmed in patients with cardiometa-
bolic diseases. Therefore, there is an urgent need to 
define the visceral obesity based on the VF cut values 
above which the risk of T2DM, dyslipidaemia, and 
cardiovascular diseases is increased.
Opposite to visceral obesity, abdominal obesity 
is well-defined based on the measurements of waist 
circumference (WC). Importantly, WC may also be 
a good surrogate indicator of visceral obesity, because 
it correlates both with VF mass (R = 0.703) and vo-
lume (R = 0.701) determined by DXA [26].
Visceral fat and metabolic disorders
The results of many studies suggest that an ex-
cess of VF increases the risk of cardiovascular and 
metabolic disorders, mainly the conditions that are 
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Figure 1. Visceral fat measured by dual-energy X-ray absorptiometry 
The image is taken from own database
Table II. Metabolic abnormalities associated with proliferation  
of visceral fat and extra-abdominal fat depots
Insulin resistance and type 2 diabetes










Increased prothrombotic activity in arteries and veins
Sarcopoenia
closely related to a reduced insulin sensitivity (Ta-
ble II). However, regardless of the method used for 
assessment, the VF mass, volume, or cross-sectional 
area are linearly associated with indices of insulin 
resistance and risks of impaired glucose tolerance and 
T2DM [27−31]. A crucial role in this process seems 
to play accumulation of triglycerides and fatty acids 
in abdominal organs as a result of excessive feeding 
and increased lipolysis in VF. High concentrations of 
triglycerides in the blood of the portal vein can accu-
mulate in adjacent organs, initiating non-alcoholic 
fatty liver disease (NAFLD) and non-alcoholic fatty 
pancreas disease (NAPLD). 
NAFLD includes a wide range of morphological 
abnormalities in the organ structure from mild ste-
atosis throughout fibrosis and chronic liver inflam-
mation to cirrhosis and even hepatocellular carcino-
ma [32]. It is believed that NAFLD is also a strong 
predictor of impaired glucose homeostasis because as 
many as 93% of patients with NAFLD and baseline 
fasting glucose above 89 mg/dl may develop pre-dia-
betes within seven years [33]. This may apply not 
only to obese but even to normal weight subjects, 
particularly in cases with elevated levels of liver en-
zymes: gamma-glutamyl-transpeptidase and alanine 
aminotransferase. The latter enzyme was proposed 
as an early marker of T2DM risk [34]. NAFLD can 
be a marker of ectopic extra-abdominal fat depots, 
chronic systemic inflammation, dyslipidaemia, oxi-
dative stress, and cardiovascular disease [35].
In turn, the NAFPD leads to remodelling of the 
organ structure, which predisposes to acute or chro-
nic inflammation and pancreatic cancer. It has been 
also suggested that NAFPD, similarly as NAFLD, 
may be a marker of impaired glucose tolerance and 
T2DM [36].
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Table III. Diagnostic criteria of sarcopoenia
European Working Group on Sarcopoenia in Older People 2010 International Working Group on Sarcopoenia 2011 
Low muscle mass and:
Low muscle strength or: 
Low physical performance
Recommended methods of evaluation: computed tomography, reso-
nance imaging, DXA, bioelectric impedance analysis
Low muscle mass in conjunction or not with increased fatty tissue  
and impairment of muscle function
Recommended methods of evaluation: DXA
Table IV. Diagnostic criteria of sarcopoenic obesity
Obesity (total body fat) Sarcopoenia (muscle mass) Reference
> 27% (M) and > 38% (F) of body weight 5.75 kg/m2 (M) and 10.75 kg/m2 (F) Batsis [64]
Two upper quintiles Three lower quintiles Zoico [66]
Upper quintile Lower quintile Kim [67]
Extra-abdominal visceral fat depots
Recently, more attention has been paid to ex-
tra-abdominal fat depots (Table III). They can be 
found in the heart, arterial walls and kidneys. Ex-
tra-abdominal depots develop mainly in obese, but 
can also be identified in overweight or normal weight 
individuals, particularly in those with excess intra-ab-
dominal fat [37–41]. 
Adipocytes in fat depots exhibit similar morpho-
logical and functional properties as those accumula-
ted in VF. After macrophages infiltration, they secrete 
pro-inflammatory cytokines into the blood, which 
induce a low-grade, non-infectious inflammation 
[41, 42]. In addition, extra-abdominal fat depots 
may exert unfavourable local effects. In the heart, the 
adipose tissue can accumulate in cardiomyocytes, epi-
cardium and pericardium [43]. Excessive uptake and 
oxidation of fatty acids in cardiomyocytes produce 
lipotoxicity, which predisposes to atrial fibrillation, 
decreased diastolic compliance of the left ventricle 
and muscle fibrosis, leading to heart failure [44].
Under physiological conditions, there are small 
lipid deposits that surround the outer surface of 
large and small arteries. This perivascular adipose 
tissue (PVAT) releases adiponectin which increases 
the bioavailability of nitric oxide and activates the 
production of hydrogen peroxide. These effects are 
considered as favourable, because adiponectin likely 
attenuates the vasoconstrictor effect of circulating ca-
techolamines and leading to the lowering of systemic 
blood pressure [45]. However, in obese subjects, in 
the mechanism that has not yet been fully elucidated, 
the beneficial effect of PVAT is abolished. In obesity, 
PVAT adipocytes are hypertrophic, similarly like in 
VF. It has been suggested that hypertrophic PVAT 
adipocytes induce local hypoxia and oxidative stress, 
which may contribute to the development of the 
resistant hypertension [46]. Interestingly, effective 
bariatric surgery, at least partially, may reverse this 
process [47]. 
Clinical studies have shown that visceral obesity 
is a risk factor for low glomerular filtration rate and 
the development of chronic kidney disease [48]. Per-
irenal fat accumulation increases intrarenal pressure 
and local production of cytokines leading to hyper-
uricaemia, renal hypertension and microalbuminuria 
[49, 50]. However, it is not known whether these 
abnormalities are associated exclusively with primary 
fat proliferation in the perirenal space or rather are 
consequences of excess visceral, or total body fat. 
A particular form of ectopic adipose tissue is fat 
infiltrating striated muscles, which may contribute 
to the development of another phenotype of obesity, 
sarcopoenic obesity.
Sarcopoenia and sarcopoenic obesity
Sarcopoenia is defined as a reduction in mass and 
overall function of the skeletal muscles. Unfortunate-
ly, muscle mass can be assessed by different defini-
tions and methods of measurement (Table IV) [51, 
52], quantitative and qualitative surrogate indica-
tors of the muscle function calculated from height, 
weight and body composition [53], which signifi-
cantly hinders comparison of the results obtained 
in studies on the prevalence of sarcopoenia and its 
metabolic consequences. For example, Batsis et al. 
[54] in unselected population applied 8 commonly 
used muscle mass indices calculated by one method 
(DXA). They found that the incidence of sarcopoe-
nic obesity widely varied from 4.4% to 84% in men 
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and from 3.6% to 94% in women, depending on the 
definition used in this study.
Until recently, the term ‘sarcopoenia’ was ad-
dressed almost exclusively to the natural involutive 
process associated with ageing. Peak muscle mass is 
achieved between 30 and 40 years of age and declines 
with aging by about 8% per year to 70 years of age 
and by 15% in the next few years [55]. Overall, 
males have higher muscle mass than females. Muscle 
mass in men decreases gradually with age, while in 
women the greatest muscle mass loss occurs after 
menopause. Loss of muscle mass is accompanied 
by muscle weakness (dynapoenia), but not linearly 
in either sex [56]. Age-dependent alterations in the 
quantity and quality of the muscle tissue result from 
progressive declines in the size, number and con-
traction abilities of muscle fibres, increased amount 
of collagen and myostatin in muscles, lowered pro-
duction of the growth hormone and IGF-1, and 
impaired nerve conduction. As a result, sarcopoenia 
leads to depletion in ability to carry out everyday 
activities, increased risk of falls and fall-related fra-
gility fractures, disability, loss of independence, and 
increased risk of death [56, 57].
Moreover, recent studies have shown that elderly 
people with reduced muscle strength and mass are 
at high risk for metabolic diseases and cardiovascu-
lar events. The prevalence of metabolic syndrome 
in elderly patients with sarcopoenia is 2−3.5 times 
higher than in population with normal muscle mass 
[58], even if the waist circumference is within nor-
mal range [59]. Moon et al. observed that skeletal 
muscle mass is inversely correlated with the VF area 
and the risk of the NAFLD [60]. Sarcopoenia is also 
often associated with insulin resistance and T2DM 
[61], arterial stiffness [62], hypertension [63], and 
increased rates of overall mortality [57, 64].
In healthy individuals, the muscle mass and bone 
mass are maintained in harmonic balance with body 
weight. This is achieved via bone mechanoreceptors, 
which are stimulated by gravity and growth factors 
produced by skeletal muscles. Recent studies have 
demonstrated that in some obese elderly subjects 
this adaptive mechanism is impaired and weight gain 
does not increase muscle mass and strength. This 
observation led to implementation of a concept of 
sarcopoenic obesity [65].
Sarcopoenic obesity is defined as the coexistence 
of sarcopoenia and obesity. It can be seen not only as 
a consequence of increasing period of life but also as 
a negative impact modern life style on muscles. How-
ever, similarly to sarcopoenia and visceral obesity that 
yet have not been unequivocally defined, nor in the 
assessment of sarcopoenic obesity various referent 
cut points for muscle mass and body fat assessed by 
different methods (DXA or bioelectric impedance 
analysis) have been proposed (Table III) [64–67]. 
Notwithstanding these limitations, the prevalence of 
obesity in elderly population is estimated at 5−21%, 
depending on age, sex and ethnicity.
Compared with sarcopoenia, patients with sar-
copoenic obesity more frequently suffer from mo-
toric dysfunction, metabolic syndrome, dyslipidae-
mia, and insulin resistance [61, 68]. The Study of 
Korea National Health and Nutrition Examination 
Surveys 2008–2010 showed similar relationship of 
sarcopoenic obesity with the risk of hypertension. 
In the general population above 60 years of age with 
normal BMI and muscle mass, the prevalence of 
hypertension was 50%; in those with normal BMI 
and sarcopoenia the risk of hypertension increased 
1.5-fold; with BMI above 25 kg/m2 and normal 
muscle mass — more than 2-fold; while with BMI 
above 25 kg/m2 and sarcopoenia, i.e. in sarcopoenic 
obesity — even up to 3-fold [63].
Aside from ageing, infiltration of muscles by the 
adipose tissue and macrophages may play a role in 
the development of sarcopoenic obesity. There is 
increasing evidence that sedentary lifestyle, low phy-
sical activity and a high-fat diet may induce this pro-
cess more than advancing age [69, 70]. Moreover, 
low vitamin D concentration, which is commonly 
observed in elderly people, appears to exert an addi-
tive effect [71]. Infiltration of muscles by the adipose 
tissue leads not only to sarcopoenia but also increases 
systemic insulin resistance [70].
The role of subcutaneous fat  
in the development of visceral obesity 
and extra-abdominal fat depots
Majority of studies cited in this review had 
a cross-sectional design. Hence, the associations be-
tween independent factors and outcome variables do 
not necessarily represent causal relationships. The 
same issue may apply to the causes of extra-abdomi-
nal fat depots. However, a growing body of evidence 
suggests that extra-abdominal fat storage is initiated 
by excessive calorie intake, which in combination 
with low energy expenditure, results in the increased 
deposition of triglycerides in the subcutaneous fat 
(SAT). Positive energy balance leads to increases in 
adipocytes size and overfilling with triglycerides of 
the SAT capacity, resulting in subcutaneous obesity 
[72], which was previously considered as metaboli-
cally neutral. However, new studies have shown that 
the excess SAT in the abdominal area (particularly 
arterial hypertension 2015, vol. 19, no. 1
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in its deeper layers) increases insulin resistance in 
the liver and systemic insulin resistance, a 10-year 
cardiovascular risk assessed by the Framingham Risk 
Score, plasma saturated fatty acids concentration, 
and expression of genes that encode inflammatory 
cytokines production, lipogenesis and lipolysis [73]. 
When SAT is not capable of storing excess ener-
gy substances, it releases fatty acids into the blood-
stream, which may accumulate in the liver, pancreas, 
skeletal muscles and lead to lipodystrophy [74] and 
lipotoxicity [75, 76]. In this context, when SAT fails 
to store excess triglycerides, fat depots proliferate 
in intra- and extra-abdominal sites [76]. This pro-
cess, as mentioned above, can be also initiated or 
accelerated by excess of exogenous or endogenous 
glucocorticoids. Fat depots, accumulated out of the 
SAT, may exert various local effects and increase 
systemic insulin resistance. Hence, it can be assumed 
that extra-abdominal fat plays a similar role in the 
pathogenesis of metabolic diseases as VF. 
In addition, infiltration of skeletal muscles adi-
pocytes and inflammatory cells results in significant 
alterations in muscle functions. In normal conditions, 
muscles produce myokines (myonectin, irisin) that 
regulate the muscle fibre contraction. When infiltra-
tion of adipocytes increases, expression of adipomyok-
ines in muscles is also increased. Adipomiokines are 
proteins (IL-6, IL-8, monocyte chemotactic protein, 
myostatin, plasminogen activator inhibitor 1, and 
some growth factors) produced both by myocytes and 
adipocytes and they exert a competitive activity to 
the myokines [77]. This positive feedback loop may 
enhance negative changes in motoric muscle units 
leading to a further weakening of muscles [76, 77].
In summary, many individuals prone to metabolic 
diseases appear to show, for a giving weight, a greater 
propensity to accumulate fat outside of SAT. This 
characteristic may be a downstream consequence of 
an ‘oversaturation’ of subcutaneous fat storage capaci-
ty. VF and ectopic fat including muscle fat, despite of 
its relatively much lower overall mass in comparison 
to SAT, may exert not only various unfavourable 
local effects but also enhance systemic insulin resis-
tance. On the other hand, some individuals with so-
called normal weight obesity or those who attained 
extremely high weight remain normoglycaemic and 
normolypaemic and have normal blood pressure. These 
individuals usually have low levels of VF and ectopic fat, 
normal muscle mass but a high subcutaneous fat content. 
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